Companies / Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc.

Nasdaq: IKTCIK 1750149WILMINGTON, DE

Financials · FY2024

Revenue$0
Net income$-48.26M
Total debt$381.8K
Cash$178.80M
Diluted EPS$-0.49
Shares outstanding139.5M

Ownership

139.5M shares outstanding · as of Aug 4, 2026
0.88%Insiders
Ownership
Insiders0.88%1,225,336
Institutions81.96%114,366,917
Public float17.16%23,943,647

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 6

View all →
Insider% of sharesShares
Cabell ChristopherPresident & Head of R&D
0.48%676,564
Aurentz VincentDirector
0.37%510,596
Munshi AmitDirector
0.03%38,176
Berman Dennis NDirector
——
Iwicki Mark TCEOChief Executive Officer · Director
——
McIntyre DavidChief Financial Officer
——

Institutional holders 83

View all →
HolderValue% of shares
Sands Capital Alternatives, LLC$26.69M9.33%
Soleus Capital Management, L.P.$22.29M7.79%
Fairmount Funds Management LLC$17.68M6.18%
ADAR1 Capital Management, LLC$16.53M5.78%
BlackRock, Inc.$15.77M5.57%
Trails Edge Capital Partners, LP$12.67M4.43%
Siren, L.L.C.$11.99M4.19%
Commodore Capital LP$11.06M3.87%
Blackstone Inc$9.98M4.26%
Vanguard Group Inc$9.35M3.27%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Feb 21, 2026Cabell Christopher
Executive
OtherCommon Stock$0-338K
-33.33%
676,564
0.48% of shares
low
Feb 21, 2026Aurentz Vincent
Director
OtherCommon Stock$0-255K
-33.33%
510,596
0.37% of shares
low
Feb 21, 2026Munshi Amit
Director
OtherCommon Stock$0-19K
-33.33%
38,176
0.03% of shares
low
Jun 26, 2026Berman Dennis N
Director
GrantStock Option (Right to Buy)—+155K
155,000
0.11% of shares
low
Jan 5, 2026Cabell Christopher
Executive
GrantStock Option (Right to Buy)—+900K
900,117
0.65% of shares
low
Jan 5, 2026Iwicki Mark T
CEO
GrantStock Option (Right to Buy)—+5.0M
4,982,706
3.57% of shares
low
Jan 5, 2026McIntyre David
Executive
GrantStock Option (Right to Buy)—+986K
986,319
0.71% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Perceptive Advisors LLCPassive13G/A———
Nantahala Capital Management, LLCPassive13G/A———
Sands Capital Life Sciences Pulse Fund II, L.P.Passive13G/A———
Fairmount Funds Management LLCPassive13G/A———
ADAR1 Capital Management, LLCPassive13G/A———
Perceptive Advisors LLCPassive13G/A———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
IKT——45719W205—